Business Wire

NanoSteel Launches 3D Printable Tool Steel

Jaa

NanoSteel®, the leader in nanostructured steel materials, today announced the launch of its first product for the laser powder bed fusion additive manufacturing process. BLDRmetal™ L-40 is a case-hardening steel powder that provides high hardness and ductility (case hardness >70HRC, 10%+ core elongation) and prints easily on standard commercial equipment. This alloy provides superior performance to M300 maraging steel and is an alternative to difficult-to-print tool steels such as H13. Expanding the potential use of 3D printing in a wide variety of hard materials markets, BLDRmetal™ L-40 is designed to be used for parts including tools, dies, bearings and gears.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170619005159/en/

Industrial die set printed using laser powder bed fusion with NanoSteel’s BLDRmetal™ L-40 tool steel ...

Industrial die set printed using laser powder bed fusion with NanoSteel’s BLDRmetal™ L-40 tool steel (Photo: Business Wire)

The capabilities of BLDRmetal™ L-40 were demonstrated by printing an 8-inch roll thread die set, which outperformed dies machined from D2 and M2 tool steels. “We tried nearly every combination of material and conventional CNC machining process to create our dual-thread die sets, none of which could cut or grind the complicated dual-thread geometry,” said Mark Doll, President and CEO of Perfect Lock Bolt America Inc., the only manufacturer of dual-thread fasteners in North America that are resistant to self-loosening. “The NanoSteel solution delivers exactly what we are looking for, including excellent surface finish, flexibility, as well as strength and hardness for maximum die life. This is a welcomed technological innovation to the fastener industry. We have been pleased with our testing and are slated to start production this year.”

NanoSteel developed this high hardness alloy through rapid iterative development at CFK GmbH, an industry-leading 3D printing service provider, whose expertise was instrumental in developing the die from concept to finished part. “For us, the most important attributes of NanoSteel’s BLDRmetal™ L-40 are that it is easily implemented and creates crack-free high hardness components, which sets it apart from the many other tool steels we have tested” said Dr-Ing. Christoph Over, CEO at CFK. “We are proud to be a preferred printing service provider for NanoSteel, which will allow us to continue to offer the most valuable products to our customers.”

“Launching BLDRmetal™ L-40 after successfully producing the roll thread dies ensures the commercial viability of the new alloy for customers investigating the use of additive manufacturing,” said Harald Lemke, Vice President and General Manager of NanoSteel Engineered Powders. “We don’t stop at material design, but create joint solutions with our customers, facilitating the process from material selection and prototyping to fully qualified production parts.” Building off earlier products for binder jet printing, NanoSteel continues to expand its product family for additive manufacturing.

About NanoSteel
NanoSteel is an advanced materials company specializing in the design and commercialization of patented steels with exceptional mechanical properties. Current focus areas are sheet steel for automotive lightweighting applications and metal powders for 3D printing. Founded in 2002, NanoSteel is a privately held company funded by investors including GM Ventures, Lear Corporation and SPDG. For more information, visit www.nanosteelco.com or follow us on Twitter @NanoSteelCo.

Contact information

NANOSTEEL
Robyn Kennedy, 617-694-7373
rkennedy@nanosteelco.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New data presented at the American Academy of Dermatology show LEO Pharma’s Kyntheum® (brodalumab) improves psoriasis on the nail19.2.2018 09:00Tiedote

NOT FOR DISTRIBUTION IN THE UNITED STATES OR UNITED KINGDOM: LEO Pharma today announced new data demonstrating long-term improvements in psoriasis on the nail with Kyntheum® (brodalumab) when compared to placebo or ustekinumab.1 Psoriasis on the nail, which is challenging to treat,2 affects approximately half of the estimated 125 million people living with psoriasis worldwide.2,3 The data were presented at the 76th annual American Academy of Dermatology (AAD) meeting in San Diego, California, US. Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin, but also impacts emotional, psychological and physical health.4 The heavy and far-reaching burden of the disease can be disabling and stigmatising with a substantial negative impact on those affected and their families.4 Due to the visible nature of the condition, psoriasis on the nail can be particularly upsetting for patients.4 In moderate to severe cases, psoriasis on the nail can be pain

OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers18.2.2018 00:00Tiedote

Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im

CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 11:00Tiedote

Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates

Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 21:26Tiedote

Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a

General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 20:05Tiedote

General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges

Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 12:03Tiedote

Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme